Reported 2 days ago
Merck & Co., Inc. (MRK) is recognized as a reliable dividend stock among the Dogs of the Dow due to its diverse portfolio and consistent dividend growth over 16 years. The company's recent acquisition of Verona Pharma for $10 billion enhances its offerings with the promising COPD treatment Ohtuvayre. With a dividend yield of 3.82% and strong first-quarter earnings, Merck aims to leverage its innovations while some analysts predict significant sales potential from new treatments.
Source: YAHOO